Survival benefits of SGLT2 inhibitors in very elderly patients with heart failure with preserved ejection fraction
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a foundational therapy for heart failure with preserved ejection fraction (HFpEF). However, pivotal randomized clinical trials have predominantly underrepresented the elderly population, leaving the real-world efficacy of SGLT2i in this specific d...